Beta Delta

Why is Wall Street Ignoring ImmunoGen?

bt redneck.. i dont think there is any conspiracy theory between dna and imgn. the phase 2 just finally dosed its 110th patient according to a patient in the trial.

dna has also announced two other phase 2 trials, both of which could be registrational according to a top dna official, sue hellmond? sp

With parent Roche, already opting in on trastuzumab-dm1 last sept 2007, this drug, barring a major side effect, and so far nothing even close to a major SE has been found, will have enough statistical significance between either of those two trials in the MBC setting to file for approval sometime in 2010. I suspect only that the possible announcement of a pivotal trial or P3 may be the trigger for a milestone payment, and thus genentech may be holding off until later this year. With genentech still on the hook for approx 37 million in future milestones, and about to enter phase 3, the milestone could approach the 10-15 million mark. Even for genentech, this is a significant cash outlay. But rest assured, it will be paid to immunogen, likely sooner than later.